E104
E104 (compound 1) is a potent and selective TLR7 agonist. E104 can be delivered by antibody-drug conjugate (ADC) technology to elicit potent anticancer activity. E104 induces the activation of mouse macrophages and hPBMCs[1].
Product Specifications
CAS Number
1610431-21-4
UNSPSC
12352203
Target
ADC Payload; Toll-like Receptor (TLR)
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/e104.html
Purity
99.38
Solubility
DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
NC1=NC2=C(C=CC=C2)C3=C1N=C(CCCC)N3CC4=CC=C(C=C4)N
Molecular Formula
C21H23N5
Molecular Weight
345.44
References & Citations
[1]DeYoung EG, et al. Synthesis and Optimization of 1-Substituted Imidazo[4,5- c]quinoline TLR7 Agonists. ACS Med Chem Lett. 2023 Sep 14;14 (10) :1358-1368.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
ADC Related
Clinical Information
No Development Reported
Isoform
TLR7
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
